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doi:10.1016/j.jmii.2012.05.009Background/Purpose: The rapid progress of biotechnology and molecular biology has led to
genetically modified (GM) crops becoming a part of agricultural production. There are concerns
that the issues of the functional ingredients in GM products have not been addressed, such as the
bioactivities of soy proteins and isoflavones. This study aimed to investigate the effects of pro-
biotic-fermented GM soy milk on hypercholesterolemia, and atherosclerotic risks in hamsters.
Methods: One hundred and twelve male Golden Syrian hamsters (Mesocricetus auratus) were
randomly assigned into 14 groups of 8 animals each. Normal- and high-cholesterol experimental
diets were supplemented with GM or non-GM soymilk with or without probiotic-fermentation for
8 weeks. Serum and fecal lipid levels were measured. Moreover, aortic plaque in artery were
stained, and thiobarbituric acid reactive substance content, super oxide dismutase activity
and caralase activity were determined.
Results: GM or non-GM soy milk with or without probiotic-fermentation significantly decreased
(p < 0.05) serum TC levels, compared with a high-cholesterol diet group. TC levels in hamsters
fed GM soy milk were not significantly different from TC levels in the non-GM soy milk group
(p > 0.05). GM soy milk groups can reduce risk of developing atherosclerosis through lowered
oxidative stress and reduced atherosclerotic plaque formation in the aorta, and are thus at least
equivalent to non-GM soy milk.
Conclusion: GM soy milk with or without probiotic-fermentation can improve hypercholesterol-
emia and reduce the risk of atherosclerosis, and is considered substantially equivalent to non-
GM soy milk in terms of these bioactive functions.
Copyright ª 2012, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All rights
reserved.ection 4, Roosevelt Road, Taipei City, Taiwan.
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2 T.-Y. Tsai et al.Introduction issues regarding consumption of GM soy products, hypo-
cholesterolemia and improvement of atherosclerotic risksThe rapid progress of biotechnology and molecular biology
has led to genetically modified (GM) crops becoming a part
of agricultural production. From 1996 to 2010, 964
approvals for GM crops were granted worldwide. Soybean
and corn are the top two most widely grown GM crops.1
Soybean-related products, such as soy milk, are tradi-
tional cuisine consumed in Asia. Soybean provides high-
quality proteins, fats, and carbohydrates and contains no
cholesterol or lactose. It is a plentiful and inexpensive
source of nutrition for lactose-intolerant individuals,
vegetarians, and milk-allergy patients.2 The undigested
pepsin fraction of soybean protein effects the fecal
excretion of steroids or bile acids, which may influence
cholesterol metabolism.3 Also, the mechanism for the
hypocholesterolemic effect of soy milk is indicated that
non-absorbed nitrogen-containing substances are corre-
lated with the lipid-lowering effect.4 Isoflavones in
soybeans and unfermented soy foods exist in their glucoside
form, but rarely in the aglycone form. Several studies
indicate that increasing the bioavailability of these gluco-
sides requires hydrolysis of the sugar moiety by intestinal b-
glucosidase, which increases the absorptivity of aglycone
isoflavones above that of the glucoside form in healthy
adults.5,6 In previous studies, soy milk fermented with
probiotics to produce high levels of b-glucosidase improved
the nutrition and bioactivity value of the foods.7
Development of the Roundup Ready soybean required
the identification of a 5-enolpyruvylshikimate-3-phosphate
synthase (EPSPS) variant that was not affected by glyph-
osate. Although this CP4 EPSPS differs slightly from its
natural counterpart in the soy plant, the difference is
similar in degree to those found among food plants gener-
ally.8 In a previous study, compositional analyses of meals
from GM soybeans were undertaken, and defatted GM
soybean meals were found to be similar to the control meal
in total protein, fat, fiber, carbohydrates, and other
components.9 Compounds with hormone-like (e.g.,
estrogen) activities are also of interest to consumers due to
their potential effects on cellular functions.
Based on the information described in previously pub-
lished studies, GM soybeans are equivalent to non-GM
soybeans. However, as knowledge and experience with
GM foods (GMFs) increases, new questions may arise.10
Moreover, Chen11 indicate that natural content is
observed to have a negative impact on consumers’ atti-
tudes toward GM foods in Taiwan. Soybean-related prod-
ucts fermented with microorganisms, including miso and
soy sauce, are popular foods in Asia. Soy milk is also
a common beverage in Taiwan. In our previous study, fer-
mented milk and soy milk were proven to have potential
hypocholesterolemic effects, which are related to the
levels of soy proteins and isoflavones in such products.12
There have been concerns that the functional issues
underlying improvement of the hypercholesterolemic
effects in GM and fermented soy products were not
addressed. It is of interest to study the potential effects
associated with consuming the GM soy-derived product soy
milk. Therefore, to clarify the uncertainties of functionalin hamsters by feeding GM soy milk and probiotic-
fermented GM soy milk were evaluated in this study.
Methods
Chemicals and media
Thiobarbituric acid (TBA), malondialdehyde (MDA), and
dimethyl sulfoxide (DMSO) were purchased from Sigma
Chemical Co. (St. Louis, MO, USA). Lactobacilli MRS broth
and Bacto-agar were purchased from Difco Co. (Detroit, MI,
USA). GM soybean was purchased from supermarkets (Tai-
pei, Taiwan) and non-GM soybean [Glycine max (L.) Merrill
BB50] was obtained from Chuan Gui Bio-Organic Co.
(Taoyuan, Taiwan).
Analysis and preparation of soy milk and fermented
soy milk with lactic acid bacteria
The transgenes in purchased soybeans were analyzed by
nested polymerase chain reaction (PCR) according to our
previous study.13 The preparation of soy milk was carried
out with the substrate of GM and non-GM soybeans. Briefly,
soybean was soaked in deionized water for 8 hours at 25C.
The swollen bean was ground into a homogenate with eight
times water of soybean dry weight using a blender, and the
homogenate was then filtered through a defatted cotton
sheet. The resultant slurry was filtered through a sieve and
then heated in a water bath at 90C for 1 hour. The
bacterial strain used in this study was Lactococcus lactis
subsp. lactis BCRC 14016, which was purchased from Bio-
resource Collection and Research Center, Food Industry
Research and Development Institute (Hsinchu, Taiwan). The
culture strain was inoculated 1% (v/v) to soy milk. The
cultured soy milk was incubated in flasks at 37C for
72 hours. At the end of preparation, all samples were dried
by freeze dryer (SDF-25, Chang Jung Business Co., Feng-
Jen, Taiwan) for analysis and feeding hamsters. Standard
methods of the Association of Official Analytical Chemists14
were used to determine the crude protein and crude fat
content. And the phenolsulfuric acid method was used to
estimate total carbohydrates.15 Crude protein (total
nitrogen (%)  6.25) was determined by the Kjeldahl
method using 2 g samples. Crude fat was obtained by
exhaustively extracting 5 g of each sample in a Soxhlet
apparatus using petroleum ether (boiling point range
40e60C) as the extractant. The glycoside and aglycone
isoflavones were analyzed by high performance liquid
chromatography (HPLC; Jasco Co., Tokyo, Japan) according
to Lin and colleagues.16
Diets and experimental eesign
One hundred and twelve male Golden Syrian hamsters
(Mesocricetus auratus) weighing 100 to 120 g were housed
in individual cages and subjected to a 12-hour light/dark
cycle with a maintained relative humidity of 50%e60%, and
GM soy milk and hypercholesterolemia 3a temperature at 25  2C. The animals were given free
access to regular rodent feed and water for 4 weeks to
adapt the new environment. Hamsters were randomly
assigned into 14 groups of eight animals each before the
animal experiment. The dose of soy milk was calculated in
accordance with Boyd’s Formula of body surface area as
recommended by the U.S. Food and Drug Administration
(FDA).17 In previous study, 15 g of total proteins contents in
non-GM soy milk was used as the reference dosage of adult
as hypocholesterolemic effects.4,12,18 All test samples were
prepared according to the reference dosage and included in
the daily total energy requirement. Samples were mixed
with experimental diets to and orally administrated to the
hamsters for 4 weeks and 8 weeks, respectively. Composi-
tion of experimental diets and samples were shown in
Table 1 and provided in accordance with AIN-76 diet
formulation with modification. The food intake was recor-
ded daily, and animals were weighed weekly. The N group
was fed a normal diet via AIN-76 formulation, and the HC
group was given a high cholesterol diet that contained 0.2%
cholesterol. GM, NGM, FGM and FNGM groups were fed the
high cholesterol diet and orally given GM soy milk, non-GM
soy milk, fermented GM soy milk and fermented non-GM soy
milk with L. lactis subsp. lactis BCRC 14016 (4.5 g/kg body
weight per day, including 15 g total proteins), respectively.
In addition, the HM group, a positive control group, was fed
the high cholesterol diet and given orally red mold rice
powder (100 mg/kg body weight per day).18 Twenty four
hours before sacrifice, all food was removed. Animals were
anesthetized by carbon dioxide inhalation and sacrificed.
Blood was collected by cardiac puncture and centrifuged at
5000g for 10 minutes at 4C to prepare plasma that was
frozen at 20C until analysis. Whole blood was collected
for the assay of superoxide dismutase (SOD) and catalase
(CAT) activities. Serum samples were obtained by drawing
the blood into a serum separated tube, allowing it to clotTable 1 Composition of the experimental diet (g/kg diet)
Composition N HC HM GM NGM FGM FNGM
Casein 200 138 138 126 119 126 122
Corn starch 650 680 680 620 587 621 603
Cellulose 50 50 50 50 50 50 50
Soybean oil 50 80 80 73 69 73 71
Mineral 35 35 35 35 35 35 35
Vitamin 10 10 10 10 10 10 10
L-cysteine 3 1 1 1 1 1 1
Choline bitartrate 2 2 2 2 2 2 2
Cholic acid d 2 2 2 2 2 2
Cholesterol d 2 2 2 2 2 2
Soy milk powder d d d 83 121 81 104
Monascus powder d d 1.67 d d d d
The experimental diet is based on the AIN-76 formula.
FGM Z fermented genetically modified soy milk and high-
cholesterol diet; FNGM Z fermented non-genetically modified
soy milk and high-cholesterol diet; GM Z genetically modified
soy milk and high cholesterol diet; HC Z high cholesterol diet;
HM Z Monascus-fermented powder and high cholesterol diet;
NZ normal diet; NGMZ non-genetically modified soy milk and
high cholesterol diet.and centrifuging for 10 minutes at 3000g to separate serum.
Liver tissue was cleaved and rinsed frequently with sterile
phosphate buffered saline (PBS) to eliminate blood and
immersed in the liquid nitrogen, and then stored at 80C.
The experiment was reviewed and approved by the Animal
Care and Research Ethics Committee of the National Taiwan
University.
Serum and liver lipid analysis
Serum and fecal total cholesterol (TC), triglyceride (TG),
and serum high density lipoprotein cholesterol (HDL-C)
levels were measured in triplicate using commercial enzy-
matic kits. These kits were as follows: TC assay kit (CH 200,
Randox Laboratories Ltd., Antrim, UK), TG assay kit (TR-
210, Randox Laboratories Ltd), and the HDL-C assay kit (CH-
203, Randox Laboratories Ltd). Serum low density lipopro-
tein cholesterol (LDL-C) levels was gained via the follow
calculation,19 LDL-C (mg/dL) Z TC e TG/5 e HDL-C. Liver
tissue (0.5 g) was ground in 10 mL of ice-cold Folch solution
(chloroform: methanol Z 2:1; v/v) and incubated for
30 minutes at room temperature. The aqueous layer was
aspirated and discarded, and the fixed volume of organic
layer was then evaporated to dryness. The dried lipid layer
were dissolved with equal volume of dimethyl sulfoxide
(DMSO) and then used to determine the TC and TG levels
using commercial enzymatic kits.
Determination of thiobarbituric acid reactive
substance content, SOD activity, and CAT activity
According to the procedure of previous study, thio-
barbituric acid reactive substance (TBARS) levels of serum
were determined by the method of thiobarbituric acid
(TBA) colorimetric analysis, and the optical density (OD)
value was measured at 532 nm.20 The SOD activity of
erythrocyte from whole blood was examined by using the
commercial kit (Ransod, Randox Laboratories Ltd). The
results were expressed for erythrocytes as U/g Hb.21 The
CAT activity of erythrocyte from whole blood was deter-
mined as previously described.22 CAT activity was measured
as consuming 10 mM H2O2 by measuring the changes in
absorbance at 240 nm for 3 minutes.
Stain of aortic plaque in artery
The thoracic aorta was cut open longitudinally along the
anterior side, the lipid-rich lesions on the surface of the
aorta were stained with 2% Sudan IV, and then washed with
gradient concentration of methanol (100%, 90%, 80%, 70%,
60%) and PBS. Whole surface area of thoracic aorta was
stained by Sudan IV and photographed using digital camera.
The aortic surface area and its stained plaque area (red)
were selected and quantitated by the Posterize program of
Photoshop 7.0 software (Adobe Systems Incorporated, San
Jose, CA, USA). The selected pixels of plaque area and
whole aorta were used to calculated percent area of the
aortic plaque, as follows:
Aortic plaque percent ð%ÞZðpixel of stained plaque area=
pixel of whole aortaÞ  100%
Table 2 Isoflavone content (mg/g) in GM soy milk, NGM soy milk, FGM soy milk, and FNGM soy milk
Soy milk Isoflavone content (mg/g)
Genistin Daidzin Genistein Daidzein
GM 88.2  2.7c 283.4  7.3d 51.7  3.7b 67.0  2.3b
NGM 70.6  0.8b 241.0  3.3c 10.3  0.8a 15.6  0.6a
FGM 3.9  0.2a 1.2  0.8a 240.8  16.8d 256.8  22.6d
FNGM 3.2  0.2a 9.6  0.0b 170.3  3.9c 210.8  0.6c
FGMZ fermented genetically modified soy milk; FNGMZ fermented non-genetically modified soy milk; GMZ genetically modified soy
milk; NGM Z non-genetically modified soy milk.
Data are presented as mean  SD, and all values represent triplicate results. Values bearing different superscript letters in the same
column are significantly different in accordance with Duncan’s multiple range test where significance is defined as p < 0.05.
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Data are expressed as the mean  standard deviation (SD).
The statistical significance in the biochemical effects was
determined by one-way analysis of variance (ANOVA) fol-
lowed by the Duncan’s multiple range tests. Values bearing
different superscript letters in the same column are
significantly different in accordance with Duncan’s
multiple range test where significance is defined as
p < 0.05.
Results
Analysis of the transgenes and isoflavones in soy
milk
A nested PCR reaction was performed to confirm the
transgene EPSPS in the soybean, and all samples used in this
study were found to have no cross contamination during the
experimental period. Glycoside isoflavones (genistin and
daidzin) and aglycone isoflavones (genistein and daidzein)
were analyzed after fermentation with lactic acid bacteria.
As in Table 2, genistein and daidzein increased 15.5-fold
(from 10.3  0.8 mg/g to 170.3  3.9 mg/g) and 12.5-fold
(from 15.6  0.6 mg/g to 210.8  0.6 mg/g), respectively,Table 3 Effect of GM and non-GM soy milk on serum and liver
Group* Serum TC (mg/dL)
4 wks 8 wks
N 59.8  6.3a 109.8  6.2a
HC 82.0  10.1b 154.2  22.8
HM 65.7  6.4a 123.0  10.8
GM 65.6  9.0a 140.1  4.9c
NGM 60.3  8.9a 131.4  12.7
FGM 59.7  9.3a 134.7  11.3
FNGM 56.6  9.4a 127.5  9.8b
Data are presented as mean  SD (nZ 8), and all values represent tr
same column are significantly different in accordance with Duncan’s
FGM Z fermented genetically modified soy milk and high-cholesterol
high-cholesterol diet; GM Z genetically modified soy milk and high
fermented powder and high cholesterol diet; N Z normal diet; NGM
TC Z total cholesterol.following 16-hour fermentation with L lactis subsp. lactis
BCRC 14016. Genistin and daidzin decreased by 95.5 and
96.0%, respectively, during this period of fermentation.
Changes in body weight and daily food intake
There was no significant difference (p > 0.05) between
body weight and daily food intake among the various groups
(data not shown). Body weights increased normally during
the period of the practical experiment. In addition, the
behavior and health of all experimental animals were
normal.
Hypolipidemic effects in the serum and liver
As shown in Table 3, high-cholesterol diet increased the
serum TC levels of hamsters in the HC group by 37.1 and
40.4% (p < 0.05), respectively, after the 4- and 8-week
feeding regimes as compared with the N group. The TC
levels of other high-cholesterol diet groups that were
administered Monascus-fermented powder (HM), GM soy
milk (GM) and non-GM soy milk (NGF) decreased signifi-
cantly by 19.9, 20.0 and 26.5%, respectively, after 4 weeks
and by 20.2, 9.1, and 14.8%, respectively, after 8 weeks of
feeding compared with the HC group (p < 0.05). The serumTC levels
Liver TC (mg/dL)
4 wks 8 wks
55.4  14.8a 93.9  36.8b
d 78.4  12.3b 139.7  30.8c
b 54.1  11.2a 55.5  12.7a
80.1  15.8b 84.7  13.7b
bc 88.0  18.7b 102.5  35.2b
bc 85.3  9.2b 91.8  6.8b
c 83.3  8.1b 84.5  23.8b
iplicate results. Values bearing different superscript letters in the
multiple range test where significance is defined as p < 0.05.
diet; FNGM Z fermented non-genetically modified soy milk and
cholesterol diet; HC Z high cholesterol diet; HM Z Monascus-
Z non-genetically modified soy milk and high cholesterol diet;
Table 4 Effect of GM and non-GM soy milk on serum HDL-C and LDL-C levels
Group* HDL-C (mg/dL) LDL-C (mg/dL) LDL-C/HDL-C ratio
4 wks 8 wks 4 wks 8 wks 4 wks 8 wks
N 31.0  5.4a 57.4  6.7a 9.74  7.2ab 33.2  7.8a 0.3  0.3ab 0.6  0.1a
HC 35.1  4.1a 65.6  7.3ab 28.0  8.1c 69.7  18.6c 0.8  0.2c 1.1  0.3c
HM 34.0  4.6a 61.7  8.4ab 16.6  7.5b 43.1  11.7ab 0.5  0.2b 0.7  0.2ab
GM 34.1  5.9a 63.7  6.5ab 8.1  8.4a 55.4  7.7b 0.2  0.3a 0.9  0.1bc
NGM 33.0  4.6a 59.5  7.7a 7.3  6.7a 54.6  8.7b 0.2  0.2a 0.9  0.1c
FGM 36.2  5.3a 69.6  6.5b 5.9  6.9a 35.3  19.0a 0.2  0.2a 0.5  0.3a
FNGM 35.6  5.4a 65.1  7.4ab 5.7  6.3a 44.2  4.5a 0.2  0.2a 0.7  0.1ab
Data are presented as mean  SD (nZ 8), and all values represent triplicate results. Values bearing different superscript letters in the
same column are significantly different in accordance with Duncan’s multiple range test where significance is defined as p < 0.05.
FGM Z fermented genetically modified soy milk and high-cholesterol diet; FNGM Z fermented non-genetically modified soy milk and
high-cholesterol diet; GM Z genetically modified soy milk and high cholesterol diet; HC Z high cholesterol diet; HDL Z high-density
lipoprotein; HMZ Monascus-fermented powder and high cholesterol diet; LDLZ low-density lipoprotein; NZ normal diet; NGMZ non-
genetically modified soy milk and high cholesterol diet.
GM soy milk and hypercholesterolemia 5TC of the FGM and FNGM groups, which were fed with
fermented GM and non-GM soy milk, was also significantly
lower than that of the HC group (p < 0.05). Furthermore,
the serum TC levels of hamsters fed GM soy milk (GM and
FGM) were not significantly different from those of the non-
GM soy milk (NGM and FNGM) groups (p > 0.05). Regarding
serum TG levels, all experimental groups fed with the high-
cholesterol diet showed no significant difference with the
HC group (p > 0.05; data not shown). In addition, the soy
milk, whether GM or non-GM, did not improve the hyper-
triglyceridemic symptoms of hypercholesterolemic
hamsters.
The effects of consuming GM or non-GM soy milk, with or
without fermentation, on lowering TC levels in the liver are
shown in Table 3. As expected, hamsters treated with
a high-cholesterol diet for 4 weeks and 8 weeks showed
a remarkable increase in liver TC levels as compared with
the N group (p < 0.05). In all treated groups, the liver TC
levels decreased significantly (p < 0.05) after the 8-week
feeding pattern compared with the HC groups. Neverthe-
less, there was no significant difference between GM and
non-GM soy milk, with or without fermentation.Table 5 Effect of GM and non-GM soy milk on blood catalase le
Group Catalase activity (units/g Hb) SOD acti
4 wks 8 wks 4 wks
N 2.6  1.2a 7.6  1.3c 187.7  34.6a
HC 2.2  0.7a 5.0  1.3a 244.5  72.6a
HM 2.3  0.9a 6.7  1.6bc 208.3  34.9a
GM 1.2  0.5a 5.9  0.9ab 327.3  96.7b
NGM 2.6  1.4a 7.0  1.7bc 412.4  67.2c
FGM 2.7  1.4a 6.6  1.7bc 429.2  43.5c
FNGM 4.2  2.4b 7.1  0.8bc 448.1  32.0c
Data are presented as mean  SD (nZ 8) and all values are based on r
the same column are significantly different in accordance with Dunca
FGM Z fermented genetically modified soy milk and high-cholesterol
high-cholesterol diet; GM Z genetically modified soy milk and high
fermented powder and high cholesterol diet; MDAZ malondialdehyde
high cholesterol diet; SOD Z superoxide dismutase; TBARS Z thiobaEffect of feeding on serum HDL-C, LDL-C, and LDL-
C/HDL-C levels
As shown in Table 4, feeding the hamsters with a high-
cholesterol diet (HC group) resulted in significantly
higher LDL-C levels than those in the N group (p < 0.05).
LDL-C levels significantly decreased in all treated groups
(p < 0.05) after feeding with soy milk compared with the
HC group. Additionally, there was no significant differ-
ence between the groups fed with GM and non-GM soy
milk, with or without fermentation, in terms of lowering
of LDL-C levels after 4 weeks of feeding. In the HDL-C
analysis, the high-cholesterol diet did not increase the
levels of HDL-C in serum compared with the N group after
4- and 8-week feeding patterns. However, the present
study indicated that a high-cholesterol diet with soy milk
would lead to a significant decrease in the ratio of LDL-C
to HDL-C compared with the HC group (p < 0.05) after 4
weeks of feeding and that there was no difference
between GM and non-GM soy milk in this regard. The
results obtained by a statistical analysis showed that the
ratio of LDL-C to HDL-C was less by 75.0% in the non-vels, SOD activity, and TBARS
vity (units/g Hb) TBARS (mM MDA)
8 wks 4 wks 8 wks
104.6  8.6a 2.2  0.3abc 2.0  0.3c
101.7  18.3a 2.2  0.9bc 2.1  0.3c
104.1  18.3a 2.8  0.4d 1.6  0.3ab
121.1  23.7ab 2.6  0.5cd 2.6  0.3d
110.5  14.6ab 1.9  0.5ab 2.3  0.4cd
126.4  20.8b 1.7  0.6ab 1.9  0.6bc
114.6  12.0ab 1.5  0.3a 1.4  0.5a
esults of triplicates. Values bearing different superscript letters in
n’s multiple range test where significance is defined as p < 0.05.
diet; FNGM Z fermented non-genetically modified soy milk and
cholesterol diet; HC Z high cholesterol diet; HM Z Monascus-
; NZ normal diet; NGMZ non-genetically modified soy milk and
rbituric acid reactive substance.
6 T.-Y. Tsai et al.fermented groups (GM and NGM) and fermented soy milk
groups (FGM and FNGM) than in the HC group (p < 0.05)
after 4 weeks of feeding. Moreover, fermented GM and
non-GM soy milk, fed for 8 weeks, had a significant effect
(p < 0.05) on lowering the ratio of LDL-C to HDL-C;
however, unfermented milk did not (p > 0.05) when
compared with the HC group.Exper
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Figure 1. Effects of GM and non-GM soy milk, with or without fer
hypercholesterolemic hamsters. (A) Atherosclerotic plaques are in
area taken up by the atherosclerotic plaques in the aorta. Abbre
presented as mean  SD (n Z 8), and values bearing different l
multiple range test where significance is defined as p < 0.05.Analysis of the atherosclerotic plaques
As shown in Table 5, feeding with GM or non-GM soy milk,
with or without fermentation, significantly enhanced SOD
activities by 33.87 (p < 0.05), 68.67 (p < 0.05), 75.54
(p < 0.05) and 83.27% (p < 0.05), respectively, after 4
weeks of feeding. CAT activity assays were performed inimental groups
GM NGM FGM FNGM
HM 
FGM FNGM 
mentation, on atherosclerotic plaques in the thoracic aortas of
dicated by the red dye in the graph; (B) the proportion of the
viation meaning of each group is shown in Table 3. Data are
etters are significantly different in accordance with Duncan’s
GM soy milk and hypercholesterolemia 7the present study, and the results revealed that the activity
of CAT in the non-GM soy milk, with or without fermenta-
tion (NGM and FNGM), and in the GM-fermented soy milk
groups (FGM) increased significantly by 40.0 (p < 0.05), 42.0
(p < 0.05) and 32.0% (p < 0.05), respectively, after feeding
for 8 weeks. A TBARS assay was used to evaluate lipid
peroxidation. As the results demonstrate, fermented non-
GM soy milk significantly decreased the TBARS levels of
serum in hamsters (p < 0.05) after 4 and 8 weeks of
feeding, compared with the HC group. In summary, soy
milk, especially fermented non-GM soy milk, improves
antioxidant activities in hypercholesterolemic hamsters.
Atherosclerotic plaques in the aorta are caused by
oxidative stress and lipid accumulation, which causes the
formation of atheromatous lesions in atherosclerosis. As
illustrated in Fig. 1, the lipid plaques accumulate signifi-
cantly in the aorta of hypercholesterolemic hamsters, taking
up 16.27% of the total area on average. The formation of
lipid plaques in the aorta was significantly decreased
(p < 0.05) compared with the HC group, after feeding with
GM and non-GM soy milk, with or without fermentation. In
the GM and non-GM soy milk groups, the areas of lipid pla-
ques in the aorta were 0.19 and 0.17%, respectively. Lipid
plaques formed over 0.16 and 0.14% of the aortic area,
respectively, in the fermented GM and non-GM soy milk
groups. All soy milk preparations that were tested appeared
to significantly improve the accumulation of atherosclerotic
plaques in the hamster aorta compared with the HC group.Discussion
According to the information from the GM crop database in
the Center Environmental Risk Assessment, 144 GM crops
have been approved for use in markets around the world.23
With the development of GM crops, there has been
a growing interest in the approaches available to assess the
potential safety of novel geneproducts. In this current study,
two types of soy milk, GM and non-GM soy milk, were man-
ufactured by our laboratory, and the transgene in these
products was carefully determined in different batches of
soy milk. A cholesterol-rich diet was associated with an
increased risk for the development of dyslipidemia. This
profile, elicited by an unhealthy dietary pattern, was
reversedwhenGM or non-GM soymilk, either with or without
fermentation, was consumed. Over a 4-week feeding
pattern, there was no statistically significant difference
between animals given food containing GM or non-GM soy
milk, whether fermented or not, on reduction in cholesterol
levels or the ratio of LDL-C and HDL-C in the serum and liver.
Moreover, unfermented soymilk did not decrease the LDL-C/
HDL-C ratio in long-termexperiments in either theGMor non-
GMgroups over 8weeks. High-cholesterol diets increased the
accumulation of LDL-C over a long-term feeding period.
Previous studies indicated that some kinds of microorgan-
isms, such as Lactobacillus spp., Bacteroides spp., and Bifi-
dobacterium spp., possess endogenous b-glucosidases,
which play a role in the hydrolysis of isoflavone glycosides.24
In the current study, the lactic acid bacteria L lactis subsp.
lactis BCRC 14016 was used to prepare the GM and non-GM
fermented soy milk, and the aglycone isoflavones were bio-
converted by fermentation. These aglycone isoflavoneswere absorbed faster and in greater amounts than glucosides
when ingested in a beverage form such as soy milk,5 and, in
long-term experiments, the LDL-C/HDL-C ratio was reduced
after feeding with either GM or non-GM fermented soy milk.
In this context, the consumptionofGMsoymilk is nodifferent
from that of non-GM soy milk for improving hypercholester-
olemia in hamsters, and GM soy milk is considered substan-
tially equivalent to non-GM soy milk in terms of these
bioactive functions.
In this study, the consumption of GM and non-GM pro-
biotic-fermented soymilkwas also compared to evaluate the
reduction in oxidative stress and atherosclerotic plaque
formation. The causal relationship between blood choles-
terol levels and atherosclerosis is widely accepted; there is
already considerable interest in the possibility of using drugs
to decrease cholesterol levels.25 Also, oxidative stress is an
important risk factor in the pathogenesis of atheroscle-
rosis.26 The antioxidative enzymes in red blood cells and
serum include SOD, seleno-dependent glutathione peroxi-
dase, glutathione reductase, and CAT.27 In our previous
study, increase in total antioxidant status and SOD activity
and decrease in lipid oxidation was observed in the blood of
hypercholesterolemic hamsters. Formation of atheroscle-
rotic plaques was repressed by the milk-soy milk fermented
by lactic acid bacteria and red mold rice.12,18 In addition,
previous studies have indicated that aglycone isoflavones
exhibit free radical-scavenging action and that soy is a rich
source of antioxidants.28 Je and colleagues29,30 also
demonstrated that peptides with antioxidant activity can be
obtained from enzyme hydrolyzed protein. A soy-enriched
diet offered to rats could help repress the oxidative
stresses and preserve their heart function after myocardial
ischemia.22 In current study, the increase of peptides which
were digested by the enzymes in digestive tract exerted
antioxidant effect by feeding with non-fermented soy milk
and provided the similarity effect on antioxidant activity
with probiotic-fermented soy milk. The changes in SOD
activities in hypercholesterolemic hamsters were elevated
by feeding them with GM and non-GM soy milk, with or
without fermentation. Additionally, increasedCATactivity in
the blood of hypercholesterolemic hamsters was observed
after feeding them with non-GM soy milk and fermented GM
and non-GM soy milk. In summary, oxidative stress was
reduced by feeding hamsters with soy milk, especially fer-
mented non-GM soy milk. Moreover, the formation of
atherosclerotic plaques was reduced after feeding with GM
and non-GM soymilk. All types of soymilk that aremade from
GM or non-GM soy reduce the symptoms of hypercholester-
olemia and the risk of atherosclerosis in hamsters.
This study is the first to demonstrate an improvement in
hypocholesterolemic symptoms and anti-atherosclerotic
effects in hamsters fed with GM and non-GM soy milk,
with or without fermentation by lactic acid bacteria. GM
soy-derived products can improve hypercholesterolemia
and reduce the risk of atherosclerosis. Thus, GM fermented
soy milk is considered substantially equivalent to non-GM
soy milk in terms of these bioactive functions.
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